Camilleri P - Search Results

1

'Case of the Month' from the Department of Urology, Oxford University Hospitals, Oxford, UK: stereotactic radiotherapy to the vas deferens for PSMA-PET CT detected local recurrence 10 years after radical prostatectomy.

Bates AS, Sharma AD, Camilleri P, Browning L, Verrill C, Hamdy FC. Bates AS, et al. Among authors: camilleri p. BJU Int. 2024 Apr 22. doi: 10.1111/bju.16373. Online ahead of print. BJU Int. 2024. PMID: 38644731 No abstract available.

2

Factors influencing local control after MR-guided stereotactic body radiotherapy (MRgSBRT) for adrenal metastases.

Ugurluer G, Schneiders FL, Corradini S, Boldrini L, Kotecha R, Kelly P, Portelance L, Camilleri P, Ben-David MA, Poiset S, Marschner SN, Panza G, Kutuk T, Palacios MA, Castelluccia A, Zoto Mustafayev T, Atalar B, Senan S, Ozyar E. Ugurluer G, et al. Among authors: camilleri p. Clin Transl Radiat Oncol. 2024 Feb 29;46:100756. doi: 10.1016/j.ctro.2024.100756. eCollection 2024 May. Clin Transl Radiat Oncol. 2024. PMID: 38450219 Free PMC article.

3

A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).

Wolfe S, Diven MA, Marciscano AE, Zhou XK, Kishan AU, Steinberg ML, Miccio JA, Camilleri P, Nagar H. Wolfe S, et al. Among authors: camilleri p. BMC Cancer. 2023 Sep 30;23(1):923. doi: 10.1186/s12885-023-11430-z. BMC Cancer. 2023. PMID: 37777738 Free PMC article. Clinical Trial.

4

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial.

Tree AC, Ostler P, van der Voet H, Chu W, Loblaw A, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Armstrong J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Duffton A, Brand DH, Henderson D, Morrison K, Brown S, Pugh J, Burnett S, Mahmud M, Hinder V, Naismith O, Hall E, van As N; PACE Trial Investigators. Tree AC, et al. Among authors: camilleri p. Lancet Oncol. 2022 Oct;23(10):1308-1320. doi: 10.1016/S1470-2045(22)00517-4. Epub 2022 Sep 13. Lancet Oncol. 2022. PMID: 36113498 Free article. Clinical Trial.

5

Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and Asia.

Slotman BJ, Clark MA, Özyar E, Kim M, Itami J, Tallet A, Debus J, Pfeffer R, Gentile P, Hama Y, Andratschke N, Riou O, Camilleri P, Belka C, Quivrin M, Kim B, Pedersen A, van Overeem Felter M, Kim YI, Kim JH, Fuss M, Valentini V. Slotman BJ, et al. Among authors: camilleri p. Radiat Oncol. 2022 Aug 22;17(1):146. doi: 10.1186/s13014-022-02114-2. Radiat Oncol. 2022. PMID: 35996192 Free PMC article.

6

Based on 0.35 T magnetic resonance-guided radiotherapy, what are the nonisotropic PTV margins required for conventional prostate radiotherapy?

Drabble J, Das P, George B, Camilleri P, Morris A. Drabble J, et al. Among authors: camilleri p. Med Dosim. 2022 Winter;47(4):334-341. doi: 10.1016/j.meddos.2022.06.004. Epub 2022 Jul 28. Med Dosim. 2022. PMID: 35907693

7

Oxidative metabolism of razuprotafib (AKB-9778), a sulfamic acid phosphatase inhibitor, in human microsomes and recombinant human CYP2C8 enzyme.

Camilleri P, Soldo B, Buch A, Janusz J. Camilleri P, et al. Xenobiotica. 2021 Oct;51(10):1110-1121. doi: 10.1080/00498254.2021.1969482. Epub 2021 Sep 3. Xenobiotica. 2021. PMID: 34477046

8

The in vivo disposition of subcutaneous injected ¹⁴C-razuprotafib (¹⁴C-AKB-9778), a sulphamic acid phosphatase inhibitor, in nonclinical species and human.

Soldo BL, Camilleri P, Buch A, Janusz J. Soldo BL, et al. Among authors: camilleri p. Xenobiotica. 2021 Oct;51(10):1132-1145. doi: 10.1080/00498254.2021.1972358. Epub 2021 Sep 1. Xenobiotica. 2021. PMID: 34420473

9

Implementation of Stereotactic MRI-Guided Adaptive Radiotherapy (SMART) for Hepatobiliary and Pancreatic Cancers in the United Kingdom - Fifty in Five.

Gaya A, Camilleri P, Nash A, Hughes D, Good J. Gaya A, et al. Among authors: camilleri p. Cureus. 2021 May 17;13(5):e15075. doi: 10.7759/cureus.15075. Cureus. 2021. PMID: 34150409 Free PMC article.

10

Systematic approach to selecting licensed drugs for repurposing in the treatment of progressive multiple sclerosis.

Cunniffe N, Vuong KA, Ainslie D, Baker D, Beveridge J, Bickley S, Camilleri P, Craner M, Fitzgerald D, de la Fuente AG, Giovannoni G, Gray E, Hazlehurst L, Kapoor R, Kaur R, Kozlowski D, Lumicisi B, Mahad D, Neumann B, Palmer A, Peruzzotti-Jametti L, Pluchino S, Robertson J, Rothaul A, Shellard L, Smith KJ, Wilkins A, Williams A, Coles A. Cunniffe N, et al. Among authors: camilleri p. J Neurol Neurosurg Psychiatry. 2021 Mar;92(3):295-302. doi: 10.1136/jnnp-2020-324286. Epub 2020 Nov 12. J Neurol Neurosurg Psychiatry. 2021. PMID: 33184094

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

113 results

Search Page